Satellos Bioscience

Satellos Bioscience

Biotechnology
Satellos Bioscience Inc. is a Canadian biotechnology company dedicated to developing novel therapeutics for muscle regeneration. The company's research is centered on understanding and modulating the polarity of muscle stem cells to enhance their regenerative capacity. Satellos aims to address unmet medical needs in conditions characterized by muscle degeneration, such as Duchenne muscular dystrophy (DMD) and other muscular dystrophies. Through its proprietary technology platform, Satellos is working to bring innovative treatments to patients suffering from debilitating muscle disorders.

$146.7M

Market Cap • 10/13/2026

NASDAQ

Listing Exchange

Flag of Canada

Canada

Country

Valuation

P/B

2,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,9

EPS

—

Market Cap

Market Cap

146,7M

EV

84,9M

EV/Revenue

0

EV/EBITDA

-2,4

EV/EBIT

-2,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-35,9%

Total Yield

-35,9%

Payout

0%

Retained Earnings

-103,5M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

140%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

73,5%

CAGR Net Income 5Y

77,4%

CAGR EPS 5Y

7,5%

CAGR OCF 5Y

81,2%

Leverage

N.D./EBITDA

1,7

Debt/Equity

0%

Current Ratio

11,2

Quick Ratio

10,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium